At the end of summer we told you all about a new initiative of the National Brain Tumor Society called the Clinical Trial Endpoints Initiative, which aims to jumpstart brain tumor treatment development. At the time we were just getting back from an extremely fruitful meeting with the U.S. Food & Drug Administration (FDA), which […]
When The Cancer Genome Atlas (TCGA) launched in 2006, it was a huge moment for cancer research. The National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) had come together to deliver researchers a better understanding of the molecular basis of cancer through the application of genome analysis and sequencing technologies.
National Brain Tumor Society and OligoNation announced Dr. David Louis, MD, of Massachusetts General Hospital and Harvard Medical School, and Dr. Anders Persson, PhD, of The University of California, San Francisco as the first grant recipients of the Oligodendroglioma Research Fund.